Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00296244 · ClinicalTrials.gov registry record · Phase 4

Steroid Free Immunosuppression in Liver Transplantation

A Phase 4 study of Liver Cirrhosis and Liver Transplant Disorder, sponsored by Thomas Jefferson University.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT00296244: Completed Phase 4 study of Liver Cirrhosis and Liver Transplant Disorder, sponsored by Thomas Jefferson University.

NCT00296244 is a Phase 4 study of Liver Cirrhosis and Liver Transplant Disorder that has completed, run by Thomas Jefferson University. The registered enrollment target is 40 participants, below the 1,002-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00296244, a Phase 4 study of Liver Cirrhosis and Liver Transplant Disorder, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether steroid-related complications can be avoided by using steroid-free immuno-suppressive drug regimen after liver transplantation.

Primary Outcome

Percentage of recipients whose liver grafts are still working at the end of 1 and 2 years.

Conditions Studied

Liver Cirrhosis Liver Transplant Disorder

Interventions

  • DRUG Tacrolimus
  • DRUG Steroids
  • DRUG Basiliximab
  • DRUG Enteric-coated Mycophenolic acid (EC-MPA)

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2006-02
Est. Completion 2008-06
Phase Phase 4
Thomas Jefferson University

292 total trials

What the finished NCT00296244 record still lists

NCT00296244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,002-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Liver Cirrhosis appearing as the primary indexed condition, and to 4 interventions - of which Tacrolimus is the first listed.

NCT00296244 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00296244 about?

NCT00296244 is a clinical study titled "Steroid Free Immunosuppression in Liver Transplantation". The purpose of this study is to determine whether steroid-related complications can be avoided by using steroid-free immuno-suppressive drug regimen after liver transplantation.

What is the current status of trial NCT00296244?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-02. Estimated completion is 2008-06.

What conditions does trial NCT00296244 study?

This clinical trial studies the following conditions: Liver Cirrhosis, Liver Transplant Disorder.

What interventions are being tested in trial NCT00296244?

The interventions under investigation include: Tacrolimus (DRUG), Steroids (DRUG), Basiliximab (DRUG), Enteric-coated Mycophenolic acid (EC-MPA) (DRUG).

Who is sponsoring clinical trial NCT00296244?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00296244 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cirrhosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00296244's enrollment target sits among peer trials

40 13th of 15 higher than 3 of 15 other Liver Cirrhosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Liver Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00296244, the US trial registry maintained by the National Library of Medicine. NCT00296244 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.